What is HC Wainwright’s Estimate for CGEM FY2026 Earnings?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Free Report) – Stock analysts at HC Wainwright upped their FY2026 earnings estimates for Cullinan Therapeutics in a research report issued on Monday, November 16th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($3.24) per share for the year, up from their prior forecast of ($3.45). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.79) EPS, Q1 2027 earnings at ($0.81) EPS, Q2 2027 earnings at ($0.84) EPS, Q3 2027 earnings at $1.49 EPS, Q4 2027 earnings at ($0.84) EPS and FY2027 earnings at $1.00 EPS.

Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.10.

Several other brokerages have also recently weighed in on CGEM. BTIG Research lifted their price target on Cullinan Therapeutics from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Wedbush lifted their target price on shares of Cullinan Therapeutics from $42.00 to $44.00 and gave the company an “outperform” rating in a report on Wednesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Friday, October 2nd. Finally, TD Cowen upgraded shares of Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.50.

Get Our Latest Stock Analysis on Cullinan Therapeutics

Cullinan Therapeutics Stock Up 0.7%

Shares of CGEM stock opened at $9.07 on Wednesday. The stock has a market cap of $588.82 million, a PE ratio of -2.95 and a beta of -0.03. The business has a 50-day simple moving average of $14.88 and a 200-day simple moving average of $15.74. Cullinan Therapeutics has a 52-week low of $8.47 and a 52-week high of $23.19.

Institutional Investors Weigh In On Cullinan Therapeutics

Hedge funds have recently modified their holdings of the business. Integrated Wealth Concepts LLC acquired a new position in shares of Cullinan Therapeutics during the 2nd quarter worth approximately $25,000. GAMMA Investing LLC grew its position in shares of Cullinan Therapeutics by 38.3% in the third quarter. GAMMA Investing LLC now owns 2,666 shares of the company’s stock valued at $41,000 after purchasing an additional 738 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Cullinan Therapeutics in the third quarter valued at approximately $50,000. Allworth Financial LP acquired a new stake in shares of Cullinan Therapeutics in the second quarter valued at approximately $53,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Cullinan Therapeutics in the second quarter valued at approximately $53,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of the firm’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the transaction, the insider owned 158,844 shares in the company, valued at approximately $3,426,265.08. This trade represents a 4.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 8.60% of the company’s stock.

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for cancer and autoimmune diseases. The company advances a pipeline of investigational medicines, including antibody-based therapies and T-cell engagers designed to direct immune responses against disease-related cells. Its programs include CLN-619, an antibody being studied for solid tumors; CLN-049, a T-cell engager targeting FLT3 for acute myeloid leukemia; and CLN-978, a CD19-targeting T-cell engager being developed for B-cell-mediated autoimmune diseases.

Read More

Earnings History and Estimates for Cullinan Therapeutics (NASDAQ:CGEM)

Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.